| 生物活性 |
N-(p-Coumaroyl) Serotonin is an orally active polyphenolic compound found in safflower seeds that exhibits potent anti-inflammatory, antioxidant, and antitumor activities; it inhibits the NF‑κB, TLR4/MyD88, and MAPK signaling pathways, activates the NQO1/HO‑1 pathway, and suppresses the expression of pro-inflammatory cytokines, iNOS, and COX‑2 as well as ROS production, induces S-phase arrest and apoptosis in glioblastoma cells, reduces atherosclerotic lesions, and alleviates renal and vascular injury, exerts vasodilatory effects and modulates calcium dynamics, and can be used in research related to neurodegenerative diseases, atherosclerosis, glioblastoma, and acute renal failure. |
体外研究 (In Vitro) |
N-(p-Coumaroyl) Serotonin (CS) (12.5-100 μM, 1 h pre-incubation + 20 h LPS challenge) 可呈剂量依赖性抑制 BV2 小胶质细胞中 LPS 诱导的 IL-6、TNF-α、MCP-1 分泌及 NO 生成。 N-(p-Coumaroyl) Serotonin (12.5-100 μM) 可显著抑制 LPS 诱导的小鼠 BV2 小胶质细胞信号级联反应。在 LPS 刺激后 60 min,它可呈剂量依赖性抑制 p38、JNK 和 ERK 丝裂原活化蛋白激酶 (MAPKs) 的磷酸化,以及 TLR4 和 MyD88 的蛋白水平;在 LPS 刺激后 20 h,它可显著降低 IκBα 和 NF-κB p65 的磷酸化水平,并抑制 p65 的核转位,从而阻断 IκB/NF-κB 信号轴的激活。 N-(p-Coumaroyl) Serotonin (12.5-100 μM; 20 h) 可呈剂量依赖性上调小鼠 BV2 小胶质细胞中 HO-1 和 NQO1 的蛋白水平。 N-(p-Coumaroyl) Serotonin (1-100 μM, 15 s pre-treatment) 可浓度依赖性地抑制 A7r5 细胞中由 KCl 和 5-HT 诱导的 [Ca2+] 升高。 N-(p-Coumaroyl) Serotonin (1-100 μM; 24 hours) 可浓度依赖性地抑制 FBS 和 PDGF-BB 诱导的 A7r5 细胞增殖,以及 PDGF-BB 诱导的 A7r5 细胞迁移。 N-(p-Coumaroyl) Serotonin (10-66 μM; 5 minutes (PDGF receptor β phosphorylation); 5, 10 minutes (ERK1/2 phosphorylation)) 可在 A7r5 细胞中抑制 PDGF-BB 诱导的 5 分钟时 PDGF 受体 β 磷酸化,以及 5 分钟和 10 分钟时 ERK1/2 的磷酸化。 N-(p-Coumaroyl) Serotonin (50-1000 μM; 72 h) 可剂量依赖性降低 U251MG、A172、D54、U87MG 和 T98G 胶质母细胞瘤细胞的活力 (IC50: 48-81 μM),其中 T98G 细胞对其敏感性高于 U251MG 细胞;而它在 MRC-5 和 HFL1 非癌成纤维细胞中的细胞毒性显著更低。 N-(p-Coumaroyl) Serotonin (50-200 μM; 72 h) 可在 U251MG 和 T98G 胶质母细胞瘤细胞中诱导剂量依赖性的 S 期细胞周期阻滞和亚 G0/G1 期细胞累积 (细胞凋亡)。 N-(p-Coumaroyl) Serotonin (77 μM; 24 h) 在 U251MG 胶质母细胞瘤细胞中激活 caspase-8。 N-(p-Coumaroyl) Serotonin (150-200 μM; 24 h) 可诱导 U251MG 胶质母细胞瘤细胞发生线粒体膜去极化。 N-(p-Coumaroyl) Serotonin (50-200 μM; 72 h) 可在 U251MG 和 T98G 胶质母细胞瘤细胞中诱导 CD71 和 CD15 表达呈剂量依赖性升高,而 CD24、CD44 和 CD56 的表达则无变化。
Cell Cytotoxicity Assay
| Cell Line: |
murine BV2 microglial cells |
| Concentration: |
6.25, 12.5, 25, 50, 100,200 μM |
| Incubation Time: |
24 h |
| Result: |
Remained unaffected at concentrations up to 100 μM. Reduced cellular viability at 200 μM. |
ELISA Assay
| Cell Line: |
LPS-challenged murine BV2 microglial cells |
| Concentration: |
12.5, 25, 50, 100 μM |
| Incubation Time: |
1 h pre-incubation, followed by 20 h LPS challenge |
| Result: |
Attenuated LPS-induced IL-6, TNF-α, and MCP-1 levels by 65.20%, 46.44%, and 30.36%, respectively. |
Western Blot Analysis
| Cell Line: |
LPS-challenged murine BV2 microglial cells |
| Concentration: |
12.5, 25, 50, 100 μM |
| Incubation Time: |
1 h pre-incubation, followed by 20 h LPS challenge |
| Result: |
Reduced LPS-induced increases in iNOS and COX-2 protein levels dose-dependently.
|
Western Blot Analysis
| Cell Line: |
LPS-challenged murine BV2 microglial cells |
| Concentration: |
12.5, 25, 50, 100 μM |
| Incubation Time: |
1 h pre-incubation, followed by 60 min LPS challenge |
| Result: |
Reduced LPS-induced phosphorylation of p38, JNK, and ERK dose-dependently. Showed significant inhibition at all tested concentrations for p38 and JNK compared to LPS-only treated cells, and significant inhibition at 50 and 100 μM for ERK. Reduced LPS-induced increases in TLR4 and MyD88 protein levels dose-dependently. Reduced LPS-induced phosphorylation of IκBα and NF-κB p65 dose-dependently, with significant inhibition observed at 25, 50, and 100 μM compared to LPS-only treated cells.
|
Immunofluorescence
| Cell Line: |
LPS-challenged murine BV2 microglial cells |
| Concentration: |
100 μM |
| Incubation Time: |
1 h pre-incubation, followed by 60 min LPS challenge (Immunocytochemistry) |
| Result: |
Inhibited LPS-induced nuclear translocation of NF-κB p65 robustly at 100 μM, sequestering the protein in the cytoplasm. |
Western Blot Analysis
| Cell Line: |
murine BV2 microglial cells |
| Concentration: |
12.5, 25, 50, 100 μM |
| Incubation Time: |
20 h |
| Result: |
Increased protein levels of HO-1 and NQO1 dose-dependently.
|
Cell Proliferation Assay
| Cell Line: |
A7r5 rat aortic vascular smooth muscle cells |
| Concentration: |
1, 10, 100 μM |
| Incubation Time: |
24 hours (with 10% FBS stimulation) |
| Result: |
Inhibited 10% FBS-induced proliferation in a concentration-dependent manner. Achieved 40% inhibition at 100 μM. |
Cell Proliferation Assay
| Cell Line: |
A7r5 rat aortic vascular smooth muscle cells |
| Concentration: |
10, 100 μM |
| Incubation Time: |
24 hours (with PDGF-BB stimulation) |
| Result: |
Inhibited 10 ng/mL PDGF-BB-induced proliferation in a concentration-dependent manner. Reduced proliferation activity to ~80% of control at 10 μM. Reduced activity to ~40% of control at 100 μM. |
Cell Migration Assay
| Cell Line: |
A7r5 rat aortic vascular smooth muscle cells |
| Concentration: |
1, 10, 66 μM |
| Incubation Time: |
4 hours (with PDGF-BB stimulation) |
| Result: |
Attenuated 10 ng/mL PDGF-BB-induced migration in a concentration-dependent manner, reducing migration absorbance to ~40%, ~35%, and ~30% of the PDGF-BB-only control at 1, 10, and 66 μM, respectively. |
Western Blot Analysis
| Cell Line: |
A7r5 rat aortic vascular smooth muscle cells |
| Concentration: |
10, 66 μM |
| Incubation Time: |
5 minutes (PDGF receptor β phosphorylation); 5, 10 minutes (ERK1/2 phosphorylation) (with PDGF-BB stimulation) |
| Result: |
Attenuated PDGF-BB-induced PDGF receptor β and ERK1/2 phosphorylation in a concentration-dependent manner, with stronger inhibition observed at 5 minutes than at 10 minutes. |
Cell Viability Assay
| Cell Line: |
U251MG, A172, D54, U87MG, T98G (glioblastoma); MRC-5, HFL1 (non-cancer fibroblast) |
| Concentration: |
50, 150, 250, 500, 1000 μM |
| Incubation Time: |
72 h |
| Result: |
Reduced viability in all glioblastoma cell lines with IC50 values of 77 μM (U251MG), 62 μM (A172), 81 μM (D54), 48 μM (U87MG), and 68 μM (T98G). Exhibited far lower cytotoxicity in non-cancer fibroblasts with an IC50 of 197 μM (MRC-5) and 181 μM (HFL1). Showed dose-dependent sensitivity in both U251MG and T98G cells, with T98G cells more sensitive than U251MG cells. Showed T98G cells greater sensitivity than U251MG cells.
|
Cell Cycle Analysis
| Cell Line: |
U251MG, T98G (glioblastoma) |
...(内容过长已截断)
体内研究 (In Vivo) |
N-(p-Coumaroyl) Serotonin (口服;持续给药;16 周) 可显著减轻 KHC 兔的主动脉壁增厚、缓解动脉粥样硬化并改善血管舒张功能。 N-(p-Coumaroyl) Serotonin (100-1000 μM; immersion; continuous; 96 hours) 对斑马鱼胚胎无急性毒性。 N-(p-coumaroyl) serotonin (每日 7.5 mg/kg 体重,灌胃,每日 1 次,连续 2 天) 对 Cisplatin (MS-E94993) 诱导的雄性 BALB/c 小鼠急性肾衰竭具有强效肾保护作用,表现为肾功能生物标志物恢复正常、氧化应激水平降低、炎症及凋亡蛋白表达受到调控,同时肾组织学形态得到改善。
| Animal Model: |
Danio rerio (embryos, 24 hours post fertilization) |
| Dosage: |
100 μM, 250 μM, 500 μM, 1000 μM |
| Administration: |
immersion; continuous; 96 hours |
| Result: |
Showed zero mortality at all tested concentrations up to 1 mM at 5 days post fertilization. |
| Animal Model: |
BALB/c (male, 7-week-old, acute renal failure model via cisplatin injection) |
| Dosage: |
7.5 mg/kg body weight per day |
| Administration: |
oral gavage; daily; 2 days |
| Result: |
Attenuated cisplatin-induced body weight loss (mean change of -3.33 g over 3 days). Prevented cisplatin-induced reduction in kidney weight (mean kidney weight of 0.44 g). Significantly reduced serum urea nitrogen level to 22.7 mg/dl. Significantly reduced serum creatinine level to 0.86 mg/dl. Markedly decreased cisplatin-induced renal reactive oxygen species (ROS) production to near-normal levels. Significantly upregulated cisplatin-reduced glutathione peroxidase (GPx) protein expression in the kidney. Significantly decreased cisplatin-induced overexpression of p-p38, p-ERK1/2, and p-JNK proteins. Significantly reduced cisplatin-induced overexpression of nuclear factor-kappa Bp65 (NF-κBp65), cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) proteins. Significantly suppressed cisplatin-induced upregulation of pro-apoptotic Bax protein and increased expression of anti-apoptotic Bcl-2 protein. Showed significant reduction in cisplatin-induced renal histological damage, including less tubular necrosis, desquamation, and parenchymal degeneration compared to vehicle-treated cisplatin-exposed mice. |
|
| 性状 |
固体 |
| 颜色 |
Off-white to light yellow |
| 分子量 |
322.36 |
| 分子式 |
C19H18N2O3 |
| CAS No. |
68573-24-0 |
| 体内实验配方 |
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.2 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 |
| 储存方式 |
| Powder |
-20°C |
3 years |
|
4°C |
2 years |
| In solvent |
-80°C |
6 months |
|
-20°C |
1 month |
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
|
溶液配制表
|
DMSO 中的溶解度 : 100 mg/mL (310.21 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO) | 可选溶剂 | 浓度 | 1 mg | 5 mg | 10 mg | 25 mg |
|---|
| DMSO | 1 mM | 3.1021 mL | 15.5106 mL | 31.0212 mL | 77.5530 mL | | 5 mM | 0.6204 mL | 3.1021 mL | 6.2042 mL | 15.5106 mL | | 10 mM | 0.3102 mL | 1.5511 mL | 3.1021 mL | 7.7553 mL | | 15 mM | 0.2068 mL | 1.0340 mL | 2.0681 mL | 5.1702 mL | | 20 mM | 0.1551 mL | 0.7755 mL | 1.5511 mL | 3.8777 mL | | 25 mM | 0.1241 mL | 0.6204 mL | 1.2408 mL | 3.1021 mL | | 30 mM | 0.1034 mL | 0.5170 mL | 1.0340 mL | 2.5851 mL | | 40 mM | 0.0776 mL | 0.3878 mL | 0.7755 mL | 1.9388 mL | | 50 mM | 0.0620 mL | 0.3102 mL | 0.6204 mL | 1.5511 mL | | 60 mM | 0.0517 mL | 0.2585 mL | 0.5170 mL | 1.2926 mL | | 80 mM | 0.0388 mL | 0.1939 mL | 0.3878 mL | 0.9694 mL | | 100 mM | 0.0310 mL | 0.1551 mL | 0.3102 mL | 0.7755 mL |
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。
|
动物实验计算换算器
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。
-
客服
2851296953
18923798467
微信洽谈
|